144 related articles for article (PubMed ID: 30771285)
21. Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer.
Zuiverloon TC; van der Aa MN; van der Kwast TH; Steyerberg EW; Lingsma HF; Bangma CH; Zwarthoff EC
Clin Cancer Res; 2010 Jun; 16(11):3011-8. PubMed ID: 20404005
[TBL] [Abstract][Full Text] [Related]
22. Urinary UBC Rapid and NMP22 Test for Bladder Cancer Surveillance in Comparison to Urinary Cytology: Results from a Prospective Single-Center Study.
Pichler R; Tulchiner G; Fritz J; Schaefer G; Horninger W; Heidegger I
Int J Med Sci; 2017; 14(9):811-819. PubMed ID: 28824318
[No Abstract] [Full Text] [Related]
23. Integrative functional genetic-epigenetic approach for selecting genes as urine biomarkers for bladder cancer diagnosis.
Eissa S; Matboli M; Essawy NO; Kotb YM
Tumour Biol; 2015 Dec; 36(12):9545-52. PubMed ID: 26138586
[TBL] [Abstract][Full Text] [Related]
24. Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations.
Kassouf W; Traboulsi SL; Schmitz-Dräger B; Palou J; Witjes JA; van Rhijn BW; Grossman HB; Kiemeney LA; Goebell PJ; Kamat AM
Urol Oncol; 2016 Oct; 34(10):460-8. PubMed ID: 27368880
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic accuracy, clinical utility and influence on decision-making of a methylation urine biomarker test in the surveillance of non-muscle-invasive bladder cancer.
D'Andrea D; Soria F; Zehetmayer S; Gust KM; Korn S; Witjes JA; Shariat SF
BJU Int; 2019 Jun; 123(6):959-967. PubMed ID: 30653818
[TBL] [Abstract][Full Text] [Related]
26. Expression signatures of exosomal long non-coding RNAs in urine serve as novel non-invasive biomarkers for diagnosis and recurrence prediction of bladder cancer.
Zhan Y; Du L; Wang L; Jiang X; Zhang S; Li J; Yan K; Duan W; Zhao Y; Wang L; Wang Y; Wang C
Mol Cancer; 2018 Sep; 17(1):142. PubMed ID: 30268126
[TBL] [Abstract][Full Text] [Related]
27. Surveillance of Low-Grade Non-Muscle Invasive Bladder Tumors Using Uromonitor: SOLUSION Trial.
Azawi N; Vásquez JL; Dreyer T; Guldhammer CS; Saber Al-Juboori RM; Nielsen AM; Jensen JB
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190269
[TBL] [Abstract][Full Text] [Related]
28. Nested quantitative PCR approach for urinary cell-free EZH2 mRNA and its potential clinical application in bladder cancer.
Zhang X; Zhang Y; Liu X; Liu T; Li P; Du L; Yang Y; Wang L; Wang C
Int J Cancer; 2016 Oct; 139(8):1830-8. PubMed ID: 27300769
[TBL] [Abstract][Full Text] [Related]
29. Investigation of Atypical Cell Parameter in the Surveillance of Patients with NMIBC; Initial Outcomes of a Single Center Prospective Study.
Karaburun MC; Özkaya MF; Ergüder Bİ; Süer E
J Med Syst; 2023 Mar; 47(1):41. PubMed ID: 36976368
[TBL] [Abstract][Full Text] [Related]
30. Value of urinary topoisomerase-IIA cell-free DNA for diagnosis of bladder cancer.
Kim YH; Yan C; Lee IS; Piao XM; Byun YJ; Jeong P; Kim WT; Yun SJ; Kim WJ
Investig Clin Urol; 2016 Mar; 57(2):106-12. PubMed ID: 26981592
[TBL] [Abstract][Full Text] [Related]
31. DETECT I & DETECT II: a study protocol for a prospective multicentre observational study to validate the UroMark assay for the detection of bladder cancer from urinary cells.
Tan WS; Feber A; Dong L; Sarpong R; Rezaee S; Rodney S; Khetrapal P; de Winter P; Ocampo F; Jalil R; Williams NR; Brew-Graves C; Kelly JD
BMC Cancer; 2017 Nov; 17(1):767. PubMed ID: 29141603
[TBL] [Abstract][Full Text] [Related]
32. Circulating miR-205: a promising biomarker for the detection and prognosis evaluation of bladder cancer.
Fang Z; Dai W; Wang X; Chen W; Shen C; Ye G; Li L
Tumour Biol; 2016 Jun; 37(6):8075-82. PubMed ID: 26715266
[TBL] [Abstract][Full Text] [Related]
33. Replacing cystoscopy by urine markers in the follow-up of patients with low-risk non-muscle-invasive bladder cancer?-An International Bladder Cancer Network project.
Schmitz-Dräger C; Bonberg N; Pesch B; Todenhöfer T; Sahin S; Behrens T; Brüning T; Schmitz-Dräger BJ
Urol Oncol; 2016 Oct; 34(10):452-9. PubMed ID: 27381893
[TBL] [Abstract][Full Text] [Related]
34. UBC
Ecke TH; Weiß S; Stephan C; Hallmann S; Arndt C; Barski D; Otto T; Gerullis H
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30513851
[TBL] [Abstract][Full Text] [Related]
35. A Novel Urine-Based Assay for Bladder Cancer Diagnosis: Multi-Institutional Validation Study.
Davis N; Shtabsky A; Lew S; Rona R; Leibovitch I; Nativ O; Cohen M; Mor Y; Lindner U; Glickman Y; Matzkin H; Tsivian A; Gofrit O; Yossepovitch O
Eur Urol Focus; 2018 Apr; 4(3):388-394. PubMed ID: 28753799
[TBL] [Abstract][Full Text] [Related]
36. Simulation of the effects of molecular urine markers in follow-up of patients with high-risk non-muscle invasive bladder cancer.
Benderska-Söder N; Ecke T; Kleinlein L; Roghmann F; Bismarck E; van Rhijn BWG; Stenzl A; Witjes JA; Todenhöfer T; Hakenberg OW; Grimm MO; Goebell PJ; Burger M; Jensen JB; Schmitz-Dräger BJ
Urol Oncol; 2024 Aug; 42(8):229-235. PubMed ID: 38403529
[TBL] [Abstract][Full Text] [Related]
37. A five-gene expression signature to predict progression in T1G3 bladder cancer.
van der Heijden AG; Mengual L; Lozano JJ; Ingelmo-Torres M; Ribal MJ; Fernández PL; Oosterwijk E; Schalken JA; Alcaraz A; Witjes JA
Eur J Cancer; 2016 Sep; 64():127-36. PubMed ID: 27414486
[TBL] [Abstract][Full Text] [Related]
38. Bladder cancer-associated gene expression signatures identified by profiling of exfoliated urothelia.
Rosser CJ; Liu L; Sun Y; Villicana P; McCullers M; Porvasnik S; Young PR; Parker AS; Goodison S
Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):444-53. PubMed ID: 19190164
[TBL] [Abstract][Full Text] [Related]
39. Prognostic relevance of positive urine markers in patients with negative cystoscopy during surveillance of bladder cancer.
Todenhöfer T; Hennenlotter J; Guttenberg P; Mohrhardt S; Kuehs U; Esser M; Aufderklamm S; Bier S; Harland N; Rausch S; Gakis G; Stenzl A; Schwentner C
BMC Cancer; 2015 Mar; 15():155. PubMed ID: 25884545
[TBL] [Abstract][Full Text] [Related]
40. A 3-plex methylation assay combined with the FGFR3 mutation assay sensitively detects recurrent bladder cancer in voided urine.
Kandimalla R; Masius R; Beukers W; Bangma CH; Orntoft TF; Dyrskjot L; van Leeuwen N; Lingsma H; van Tilborg AA; Zwarthoff EC
Clin Cancer Res; 2013 Sep; 19(17):4760-9. PubMed ID: 23842048
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]